Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flow from operating activities:
Net loss	$ (205,842,000)	$ (10,242,000)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	7,028,000	6,997,000
Non cash lease expense	(62,000)	(41,000)
Provision for doubtful accounts	456,000	981,000
Goodwill impairment	112,347,000	0
Change in fair value of warrant liabilities	(6,788,000)	(31,613,000)
Stock-based compensation expense	11,442,000	11,470,000
Change in fair value of contingent consideration	(104,339,000)	(73,441,000)
Acquired in-process research and development	3,000,000
Issuance of common stock for stem-cells to be used in research and development	1,000,000
Issuance of common stock relating to Yorkville debt extension	712,000
Discounts arising from RWI loan arrangement - related party	2,151,000
Fair value of warrant modification for professional services	403,000
Change in fair value of contingent stock consideration	(159,000)	415,000
Change in fair value of debt	354,000	291,000
Other, net	2,012,000	(1,432,000)
Changes in assets and liabilities:
Accounts receivable	(118,000)	(2,688,000)
Inventory	(1,605,000)	(16,830,000)
Prepaid expenses and other assets	2,179,000	510,000
Accounts payable	6,754,000	297,000
Accrued expenses and other liabilities	1,533,000	6,546,000
Accrued R&D Software	24,161,000
Right-of-use assets and lease liabilities	172,000	195,000
Deferred revenue	1,065,000	294,000
Net cash used in operating activities	(34,344,000)	(108,291,000)
Cash flow from investing activities:
Capital expenditures	(468,000)	(4,457,000)
Purchase of acquired in-process research and development	(3,000,000)
Net cash used in investing activities	(3,468,000)	(4,457,000)
Cash flow from financing activities:
Proceeds from RWI senior secured bridge loan and warrants - related party	12,375,000
Principal payments of Yorkville short-term debt	(16,811,000)
Proceeds from issuance of senior secured C.V. Starr bridge loan and warrants - related party	4,994,000
Proceeds from the exercise of stock options	304,000	647,000
Proceeds from the exercise of warrants		46,490,000
Proceeds from PIPE financings	12,750,000	30,000,000
Proceeds from the sale of common stock in ATM offering	136,000	4,570,000
Proceeds from other short-term debt	2,000,000	39,200,000
Proceeds from other short-term debt - related party	1,000,000
Tax withholding on vesting of restricted stock units	(87,000)
Proceeds from registered direct offerings	9,000,000
Payments of PIPE and other issuance costs	(1,553,000)	(2,754,000)
Net cash provided by financing activities	24,108,000	118,153,000
Net (decrease) increase in cash, cash equivalents and restricted cash	(13,704,000)	5,405,000
Cash, cash equivalents and restricted cash at beginning of period	28,802,000	52,076,000
Cash, cash equivalents and restricted cash at end of period	15,098,000	57,481,000
Supplemental disclosure of cash flow information:
Cash paid for interest	1,073,000
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	(752,000)	(1,014,000)
Issuance of warrants on senior secured bridge loans	2,002,000
Common stock issued for short-term debt conversion	4,599,000
Reduction of right-of-use assets and associated lease liability due to lease modification	(2,083,000)
ATM related costs included in accrued expenses		(234,000)
PIPE related costs included in accrued expenses	(69,000)	(55,000)
Interest accrued on senior secured loans within long-term debt - related parties	(1,229,000)
Reclassification of option liabilities to equity		$ 441,000
IPR&D
Adjustments to reconcile net loss to net cash used in operations:
Impairment of intangible assets, excluding goodwill	$ 107,800,000